Street Insider reports that Inovio Pharmaceuticals Inc. (NASDAQ: INO) announced the initiation and opening of sites to enroll the second portion of the company’s Phase 3 program for VGX-3100—their DNA-based immunotherapy to treat cervical dysplasia caused by human...
Pin It on Pinterest
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site you consent to our use of cookies.Ok
